Trial reportCritical care medicine2017
Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome.
Trial report in Critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01783821 (LIPS-B), which is not on this map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Who cites it
56 citing papers in PubMed, 90 citations in OpenAlex.
- Comparison of the effect of surfactant with and without budesonide on the outcomes of respiratory distress syndrome (RDS) in premature infants: a randomized control trial.BMC pregnancy and childbirth · 2025Trial
- Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19).BMJ open · 2023Trial
- Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.The Lancet. Respiratory medicine · 2021Trial
- Cardiosphere-derived cells in the primary prevention of sepsis-induced acute lung injury in pigs.PloS one · 2026Article
- One syndrome, many diseases: toward precision pharmacotherapy in acute respiratory distress syndrome.Frontiers in pharmacology · 2026Review
- Practice pattern of aerosol drug therapy in ARDS patients: A secondary analysis of the Aero-in-ICU study.Journal of intensive medicine · 2025Article
- Evaluating the Use of Inhaled Budesonide and Ipratropium Bromide Combination in Patients at High Risk of Acute Respiratory Distress Syndrome Development: A Randomized Controlled Trial.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Establishment and validation of predictive model of ARDS in critically ill patients.Journal of translational medicine · 2025Article
- Precision treatment of ventilator-induced lung injury through alveolar epithelial cell targeted lipid nanoparticle delivery.Theranostics · 2025Article
- Steroids in acute respiratory distress syndrome: A panacea or still a puzzle?World journal of critical care medicine · 2024Review
- Inhaled Corticosteroids Use Before Hospitalization May Be Protective in Children With Direct Lung Injury.CHEST critical care · 2024Article
- Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS).Respiratory research · 2024Review
- Evaluation of Preventive Pentoxifylline Effect on Acute Respiratory Distress Syndrome (ARDS) Incidence in Traumatic Patients: A Randomized Triple-Blind Placebo-Controlled Trial.Medical journal of the Islamic Republic of Iran · 2024Article
- The effect of budesonide delivered by high-frequency oscillatory ventilation on acute inflammatory response in severe lung injury in adult rabbits.Physiological research · 2023Article
- Regulator of G protein signaling protein 6 alleviates acute lung injury by inhibiting inflammation and promoting cell self-renewal in mice.Cellular & molecular biology letters · 2023Article
- Glucocorticoid Nanoparticles Show Full Therapeutic Efficacy in a Mouse Model of Acute Lung Injury and Concomitantly Reduce Adverse Effects.International journal of molecular sciences · 2023Article
- Black representation in critical care randomized controlled trials: a meta-epidemiological study.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2023Review
- Novel STING-targeted PET radiotracer for alert and therapeutic evaluation of acute lung injury.Acta pharmaceutica Sinica. B · 2023Article
- Acute Respiratory Distress Syndrome; A Review of Recent Updates and a Glance into the Future.Diagnostics (Basel, Switzerland) · 2023Review
- Pulmonary drug delivery for acute respiratory distress syndrome.Pulmonary pharmacology & therapeutics · 2023Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
objectivesEffective pharmacologic treatments directly targeting lung injury in patients with the acute respiratory distress syndrome are lacking. Early treatment with inhaled corticosteroids and beta agonists may reduce progression to acute respiratory distress syndrome by reducing lung inflammation and enhancing alveolar fluid clearance.
designDouble-blind, randomized clinical trial (ClinicalTrials.gov: NCT01783821). The primary outcome was longitudinal change in oxygen saturation divided by the FIO2 (S/F) through day 5. We also analyzed categorical change in S/F by greater than 20%. Other outcomes included need for mechanical ventilation and development of acute respiratory distress syndrome.
settingFive academic centers in the United States. PATIENTS: Adult patients admitted through the emergency department at risk for acute respiratory distress syndrome.
interventionsAerosolized budesonide/formoterol versus placebo bid for up to 5 days. MEASUREMENTS AND MAIN
resultsSixty-one patients were enrolled from September 3, 2013, to June 9, 2015. Median time from presentation to first study drug was less than 9 hours. More patients in the control group had shock at enrollment (14 vs 3 patients). The longitudinal increase in S/F was greater in the treatment group (p = 0.02) and independent of shock (p = 0.04). Categorical change in S/F improved (p = 0.01) but not after adjustment for shock (p = 0.15). More patients in the placebo group developed acute respiratory distress syndrome (7 vs 0) and required mechanical ventilation (53% vs 21%).
conclusionsEarly treatment with inhaled budesonide/formoterol in patients at risk for acute respiratory distress syndrome is feasible and improved oxygenation as assessed by S/F. These results support further study to test the efficacy of inhaled corticosteroids and beta agonists for prevention of acute respiratory distress syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.